These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 9486095)

  • 1. Impact of patient characteristics on treatment outcome: anthracycline resistance.
    Buzdar AU; Asmar L; Hortobagyi GN
    Eur J Cancer; 1997 Aug; 33 Suppl 7():S3-6. PubMed ID: 9486095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer.
    Rivera E; Valero V; Esteva FJ; Syrewicz L; Cristofanilli M; Rahman Z; Booser DJ; Hortobagyi GN
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):299-302. PubMed ID: 11914909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
    Ravdin PM
    Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter experience of nonpegylated liposomal doxorubicin use in the management of metastatic breast cancer.
    Palmieri C; Misra V; Januszewski A; Yosef H; Ashford R; Keary I; Davidson N
    Clin Breast Cancer; 2014 Apr; 14(2):85-93. PubMed ID: 24325950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of response to repeat utilization of anthracycline in recurrent breast cancer patients previously administered anthracycline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy.
    Yonemori K; Katsumata N; Kaneko M; Uno H; Matsumoto K; Kouno T; Shimizu C; Ando M; Takeuchi M; Fujiwara Y
    Breast Cancer Res Treat; 2007 Jul; 103(3):313-8. PubMed ID: 17063267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy.
    Lluch A; Ojeda B; Colomer R; Barnadas A; Massuti B; Casado A; Angeles C; Maroto P
    Cancer; 2000 Dec; 89(11):2169-75. PubMed ID: 11147586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
    Chan S
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
    Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
    BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen.
    Warner E; Hedley D; Andrulis I; Myers R; Trudeau M; Warr D; Pritchard KI; Blackstein M; Goss PE; Franssen E; Roche K; Knight S; Webster S; Fraser RA; Oldfield S; Hill W; Kates R
    Clin Cancer Res; 1998 Jun; 4(6):1451-7. PubMed ID: 9626462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy of anthracycline-resistant metastatic breast carcinoma].
    Kreienberg R
    Praxis (Bern 1994); 1998 Apr; 87(17):573-7. PubMed ID: 9623323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.
    Absmaier M; Napieralski R; Schuster T; Aubele M; Walch A; Magdolen V; Dorn J; Gross E; Harbeck N; Noske A; Kiechle M; Schmitt M
    Int J Oncol; 2018 Mar; 52(3):755-767. PubMed ID: 29328369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of docetaxel 60 mg/m2 in patients with metastatic breast cancer according to the status of anthracycline resistance.
    Ando M; Watanabe T; Nagata K; Narabayashi M; Adachi I; Katsumata N
    J Clin Oncol; 2001 Jan; 19(2):336-42. PubMed ID: 11208824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A unified definition of clinical anthracycline resistance breast cancer.
    Pivot X; Asmar L; Buzdar AU; Valero V; Hortobagyi G
    Br J Cancer; 2000 Feb; 82(3):529-34. PubMed ID: 10682660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy.
    Pierga JY; Asselain B; Jouve M; Diéras V; Carton M; Laurence V; Girre V; Beuzeboc P; Palangié T; Dorval T; Pouillart P
    Cancer; 2001 Mar; 91(6):1079-89. PubMed ID: 11267952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.
    Paridaens R; Biganzoli L; Bruning P; Klijn JG; Gamucci T; Houston S; Coleman R; Schachter J; Van Vreckem A; Sylvester R; Awada A; Wildiers J; Piccart M
    J Clin Oncol; 2000 Feb; 18(4):724-33. PubMed ID: 10673513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
    Nabholtz JM; Thuerlimann B; Bezwoda WR; Melnychuk D; Deschênes L; Douma J; Vandenberg TA; Rapoport B; Rosso R; Trillet-Lenoir V; Drbal J; Aapro MS; Alaki M; Murawsky M; Riva A
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):25-30. PubMed ID: 9364538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
    Valero V; Holmes FA; Walters RS; Theriault RL; Esparza L; Fraschini G; Fonseca GA; Bellet RE; Buzdar AU; Hortobagyi GN
    J Clin Oncol; 1995 Dec; 13(12):2886-94. PubMed ID: 8523051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.